HC Wainwright Analysts Lift Earnings Estimates for Celcuity

Celcuity, Inc. (NASDAQ:CELC) – HC Wainwright lifted their FY2027 earnings per share estimates for Celcuity in a note issued to investors on Friday, March 27th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $0.81 for the year, up from their prior estimate of $0.65. The consensus estimate for Celcuity’s current full-year earnings is ($2.62) per share. HC Wainwright also issued estimates for Celcuity’s FY2029 earnings at $7.97 EPS.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Wednesday, March 25th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.09.

Several other equities research analysts have also weighed in on CELC. Needham & Company LLC reiterated a “buy” rating and issued a $122.00 target price on shares of Celcuity in a report on Thursday. Wells Fargo & Company began coverage on shares of Celcuity in a report on Friday, December 12th. They issued an “overweight” rating and a $126.00 price target for the company. Jefferies Financial Group upped their price objective on shares of Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a research report on Tuesday, December 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celcuity in a research note on Wednesday, January 21st. Finally, Stifel Nicolaus lifted their target price on Celcuity from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.88.

Celcuity Price Performance

Celcuity stock opened at $106.02 on Monday. The firm has a market capitalization of $5.13 billion, a price-to-earnings ratio of -27.97 and a beta of 0.38. The company’s 50 day simple moving average is $109.49 and its 200 day simple moving average is $91.20. The company has a debt-to-equity ratio of 3.20, a current ratio of 10.55 and a quick ratio of 10.55. Celcuity has a fifty-two week low of $7.57 and a fifty-two week high of $120.32.

Institutional Investors Weigh In On Celcuity

A number of hedge funds and other institutional investors have recently made changes to their positions in CELC. Avoro Capital Advisors LLC bought a new stake in Celcuity in the 4th quarter valued at $310,302,000. NEA Management Company LLC increased its holdings in Celcuity by 64.9% during the 4th quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock worth $352,637,000 after purchasing an additional 1,391,300 shares in the last quarter. State Street Corp increased its holdings in Celcuity by 126.6% during the 4th quarter. State Street Corp now owns 1,637,687 shares of the company’s stock worth $163,343,000 after purchasing an additional 914,887 shares in the last quarter. Apis Capital Advisors LLC acquired a new stake in shares of Celcuity in the 3rd quarter valued at about $38,334,000. Finally, UBS Group AG raised its stake in shares of Celcuity by 910.1% in the 3rd quarter. UBS Group AG now owns 854,483 shares of the company’s stock valued at $42,211,000 after purchasing an additional 769,891 shares during the period. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Celcuity news, Director David Dalvey sold 20,000 shares of Celcuity stock in a transaction that occurred on Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total value of $2,400,600.00. Following the transaction, the director owned 90,000 shares of the company’s stock, valued at approximately $10,802,700. The trade was a 18.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 15.78% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.